浪花直播

Explore more:

Popular searches

Donate Join us

RSC Medicinal 浪花直播

The journal for research and review articles in medicinal chemistry and related drug discovery science.

Editor-in-Chief: Mike Waring

Open Access: Hybrid

RSC Medicinal 浪花直播 journal cover

RSC Medicinal 浪花直播 publishes significant research in medicinal chemistry and related drug discovery science.

ISSN: 2632-8682

Indexed in: Web of Science, Scopus, PubMed Central

Journal Impact factor

3.6 (2024)

First decision time (all)

14 days

First decision time (peer reviewed)

32 days

Scope

Research articles published in this journal must show a breakthrough or significant advance on previously published work, or bring new thinking or results that will have a strong impact in their field.

Examples of areas within the journal's scope are:

  • Design, synthesis and biological evaluation of novel chemical entities or biotherapeutic modalities. To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs.

  • Modifications of known chemical entities or biotherapeutic modalities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or provide other information of significant value, for example, the identification of a new target or mode of action for a known agent. Routine modifications with minimal or no improvement are not suitable for RSC Medicinal 浪花直播.
  • Novel methodologies and technologies in the broader chemical and biological sciences (for example, enabling synthetic chemistry, chemical biology, -omics sciences, nanoscience) with application to drug discovery, target identification or elucidation of the mechanism of action. Biological studies should present sufficient innovation with respect to the chemistry.

  • Computational studies are welcome where they significantly advance medicinal chemistry knowledge. Studies that use established computational methods should include an original prediction and be accompanied by new experimental data which validates the prediction made. Studies that report novel computational methodology must demonstrate its use in medicinal chemistry through comparison with experimental data. Computational research that does not clearly relate the results obtained to experimental data or that has no demonstrated utility (or where the utility is unlikely to advance the field significantly) is not suitable for RSC Medicinal 浪花直播. Docking studies presented without experimental data are not suitable for publication in the journal.

  • Studies that examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics.

  • Studies that present new insights into drug design based on analysis of existing experimental datasets or new theoretical approaches if supported by experimental evidence.

  • Studies presenting new drug delivery systems with novel chemical agents are welcomed, in particular those that involve chemical modification of the delivery system of conjugation with novel delivery vectors. Those that focus solely on formulations of known drugs are not suitable for publication in RSC Medicinal 浪花直播.

Note that studies where new or existing compounds are tested as pharmacological agents will only be considered if they are carried out in the presence of clear positive and negative controls. Studies of this type should include a clearly defined and hypothesis-driven compound design rationale. Potential antimicrobial agents should be tested for cytotoxicity and activity against non-related pathogens.

To help editors and referees assess the significance of each submitted manuscript we ask all authors on submission to provide a brief statement of significance. This should contain one sentence to summarise the most important finding(s) in the manuscript and a second sentence to say why this is a significant advance in the field. This significance statement should focus specifically on the importance of the piece of research being submitted, rather than the importance of the field.

Readership

Researchers in academia and industry studying medicinal chemistry, pharmacology, and topics in the wider chemical, biological and materials sciences with application to biological problems.


Information for authors

Want to publish in this journal? Our author guidelines explain how to prepare and submit your article and provide useful information on the review and publication process including transfers, revisions and any article processing charges (APCs) that may apply.

Read author guidelines

You can read our payments and funding information for further details about APCs, which may apply for publishing open access in this journal, as well available discounts and waivers.

You may be able to publish open access in this journal, with no APC to pay, if your institution has an open access agreement with us. You can use our journal finder tool to between us and your institution.

Meet the team

Mike Waring

Mike Waring

Editor-in-chief

Newcastle University

View profile
Cynthia Dowd

Cynthia Dowd

Associate editor

George Washington University

View profile
Maria Duca

Maria Duca

Associate editor

Université Côte d’Azur - CNRS

View profile
Sankar K. Guchhait

Sankar K. Guchhait

Associate editor

National Institute of Pharmaceutical Education and Research (NIPER

View profile
Susanne Müller-Knapp

Susanne Müller-Knapp

Associate editor

Goethe University Frankfurt

View profile
Sally-Ann Poulsen

Sally-Ann Poulsen

Associate editor

Griffith University

View profile
Jian Zhang

Jian Zhang

Associate editor

Shanghai Jiao Tong University

View profile
Hayley Binch

Hayley Binch

Editorial board member

Hoffman-La Roche

View profile
Paola Castaldi

Paola Castaldi

Editorial board member

MatchPoint Therapeutics

View profile
Lyn Jones

Lyn Jones

Editorial board member

Dana-Farber Cancer Institute

View profile
Jean-Louis Reymond

Jean-Louis Reymond

Editorial board member

University of Bern

View profile

Timor Baasov

Israel Institute of Technology

Andreas Bender

University of Cambridge

Julian Blagg

Institute of Cancer Research

Margaret Brimble

University of Auckland

Mark Bunnage

Vertex

Christopher Burns

Amplia Therapeutics Limited

Andrea Cavalli

University of Bologna

Young-Tae Chang

POSTECH

James Crawford

Altos Labs

Matthew Duncton

 Rigel Pharmaceuticals Inc

Stephen Frye

University of North Carolina at Chapel Hill

Matthew Fuchter

University of Oxford

Sylvie Garneau-Tsodikova

University of Kentucky

Jayanta Haldar

Jawaharlal Nehru Centre for Advanced Scientific Research

Gyoonhee Han

Yonsei University

Mike Hann

GSK Medicines Research Centre

Christian Heinis

EPFL

Laura H. Heitman

Leiden University

Yoshinori Ikeura

Axcelead Drug Discovery Partners

Ahmed Kamal

NIPER

Robert Langer

Massachusetts Institute of Technology (MIT)

Steven V Ley

University of Cambridge

María Luz López Rodríguez

Complutense University of Madrid

Christa Muller

University of Bonn

Roberto Pellicciari

University of Perugia

David Rees

Astex Therapeutics

Motonari Uesugi

Kyoto University

John C Vederas

University of Alberta

Paul Wender

Stanford University

Zhen Yang

Peking University

Ming-Qiang Zhang

Amgen

Katie Lim

Executive Editor

Hannah Fowler

Deputy Editor

Emily Cuffin-Munday

Development Editor

Sarah Anthony

Editorial Production Manager

Nicola Burton

Publishing Editor

Tom Cozens

Publishing Editor

Ryan Kean

Publishing Editor

Thomas Hitchings

Publishing Editor

Donna Smith

Publishing Editor

Sam Keltie

Publisher

David Bishop

David Bishop

Publishing Assistant

View profile

Emily Prior

Editorial Assistant

Read this journal

More from this journal

Contact the journal team

We're here to help. Contact the journal team if you have any questions about publishing your paper with us.

Sign up for journal email alerts

Get table of contents alerts and notifications about calls for papers, themed issues and more.